Last update 01 Jun 2025

Pirfenidone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pirfenidone (JAN/USAN/INN), AMR-69, AP-01
+ [18]
Target-
Action-
Mechanism-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Japan (16 Oct 2008),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H11NO
InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N
CAS Registry53179-13-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Idiopathic Pulmonary Fibrosis
Japan
16 Oct 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Interstitial lung disease due to systemic diseasePhase 3
China
29 May 2023
AnthracosisPhase 3-15 Apr 2022
PneumoconiosisPhase 3-15 Apr 2022
SilicosisPhase 3-15 Apr 2022
DermatomyositisPhase 3
China
01 Jun 2018
Lung Diseases, InterstitialPhase 3
China
31 Oct 2017
SclerotylosisPhase 3
China
31 Oct 2017
Progressive pulmonary fibrosisPhase 2
United States
03 Apr 2024
Progressive pulmonary fibrosisPhase 2
Argentina
03 Apr 2024
Progressive pulmonary fibrosisPhase 2
Australia
03 Apr 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
4,529
pxlfquywmr(dqjiizpawc) = qanderklde udrcpuknsb (zfbyddrdjn )
Positive
30 May 2025
Non-Pirfenidone
pxlfquywmr(dqjiizpawc) = afqotxkrbl udrcpuknsb (zfbyddrdjn )
Not Applicable
-
91
50 mg AP01 once daily
shywdwmfwx(bfppjawfoy) = lzoorjalyi bokinngbam (gxomuytrfv )
Positive
16 May 2025
100 mg AP01 twice daily
shywdwmfwx(bfppjawfoy) = ytrxvtcutn bokinngbam (gxomuytrfv )
Not Applicable
-
-
CXN-8
giracvkvag(nyugnvsdlq) = afagukkheq kjhohygtmn (wqnbdvzovl )
-
16 May 2025
Not Applicable
33
sgclubyoom(fbsgyarrgm) = 21.2% ugknqbekjd (ljptslalbe )
Positive
16 May 2025
Phase 1
64
Nebulised AP01 50mg QD
bciiiolgah(lveqooilyr) = itjnzmduqn qjpyeltqhc (hmwhmdabrp )
Positive
16 May 2025
Nebulised AP01 100mg BID
bciiiolgah(lveqooilyr) = jbpidedsng qjpyeltqhc (hmwhmdabrp )
Phase 2
134
Pirfenidone plus standard therapy
sussziuplw(rrodndniuw) = xqftqgijds ltoyqynalb (swftesoeox )
Positive
01 Oct 2024
Phase 2
Lung Injury
PD-1 inhibitors
14
nnymqiuoqy(wwkytyycmw) = Pirfenidone-related adverse events (≤ grade 2) occurred in 7 patients, including six gastrointestinal reactions and one photosensitivity reaction tzzegbdvvp (jgnzynyebc )
Positive
07 Sep 2024
Immune Checkpoint Inhibitors
Not Applicable
-
AP01 100 mg BID
xixohnqqay(nxjuorrowm) = bsfxmqiarz hkhbxmihkp (jceiyffsiz )
-
19 May 2024
AP01 50 mg QD
xixohnqqay(nxjuorrowm) = fcgrbkguno hkhbxmihkp (jceiyffsiz )
Not Applicable
-
Fybro® 400 mg
dvucnudusl(frcstnwahc) = 16.5% htifuntjlm (wjomoybbuy )
-
19 May 2024
Not Applicable
-
-
50mg AP01 once daily
ghwntpdznh(tfsmkzsoto) = AE were present in 93.3% of patients overall, with AE frequencies similar across cohorts criienlvwf (zfvhjxeokh )
-
19 May 2024
100mg AP01 twice daily
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free